Press release
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and
About this update from Natera, Inc.
[{"type":"text","content":"\nLargest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies.\n\nThe datasets include an oral presentation on a retrospective real-world cohort evaluating 144 patients across the spectrum of aggressive and indolent lymphomas, suggesting broad clinical applicability of Signatera for treatment response monitoring and end-of-treatment response assessment. Key findings to be presented include:\n\n\nSignatera detected recurrence prior to imaging and outperformed standard surveillance methods.\n\n\nPersonalized ctDNA detection at the end of treatment and on-treatment clearance were strong predictors of clinical outcomes across multiple lymphoma subtypes treated with standard-of-care therapy, including CAR-T cell therapy.\n\n\nEnd-of-treatment assessment with Signatera also helped to clarify ambiguous imaging results, providing important insights for disease management.\n\n\nThis clinical dataset supports the use of Signatera as a response assessment tool in lymphoma, where ctDNA-MRD was incorporated into the NCCN Guidelines in January 2025 for patients with diffuse large B-cell lymphoma.\n\n“The Signatera data at ASH highlights our commitment to advancing precision oncology for patients with blood cancers,” said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. “The findings from our real-world data reinforce the value Signatera can offer to lymphoma patients for personalized and precise care.”\n\nFull list of presentations include:\n\nDecember 6, 2:45 PM ET | Presentation # 281 (Oral Presentation)\nPresenter: Natalie Galanina, M.D.\nReal-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas\n\nDecember 6, 5:30 PM ET | Presentation # 2219\nPresenter: Yamuna Kondapally...